Louvain-la-Neuve, Belgium, and Lalaye, France (PRWEB) March 13, 2014
This is world's first comprehensive evaluation report and directory of nuclear medicine, written by experts, provides detailed information on products and companies active in this market. It is an almost 800-page report including descriptions of over 300 radiopharmaceuticals and radionuclides and more than 130 detailed profiles of companies and institutions active in nuclear medicine around the world. Next to the exhaustive description of the nuclear medicine landscape, it shows real opportunities with detailed analysis.
The global nuclear medicine market is fragmented, with more than 60 companies selling radiopharmaceuticals on a regular basis; however, three companies take more than half of the world market share whereas more than 50 companies share 14% of this same world market. While nuclear medicine is not a recent technology, the emergence of new radionuclides associated with the appearance of almost 30 new dedicated R&D companies opens a new era for this industry, which will consolidate as soon it matures. The global nuclear medicine market is now in its third S-Curve, with a number of products that are still under development. But at the same time some major companies are already starting to acquire smaller players with novel and potentially blockbuster products.
This era opens new opportunities in the nuclear medicine landscape. These opportunities have been identified not only in the radiodiagnostic area but notably in therapeutic radiopharmaceuticals, with the first products scheduled to reach the market before the end of 2020. Opportunities exist for larger groups or investors to finance such development, to merge with some partners and/or to acquire companies.
The global market is expected to reach US$ 24 billion (EUR 18 billion) in 2030, showing an annual average growth of 11%, mostly driven by the therapeutic radiopharmaceutical market which is expected to increase annually by 30% between 2013 and 2030. The diagnostic radiopharmaceutical market is expected to grow by 5% a year, mainly driven by volume increases.
“We have developed this report, a first-of-its-kind, to offer the industry and investors a valuable directory, reviewing all products and companies active in this market. I’m confident it will help people appreciate the numerous opportunities existing in the world of nuclear medicine”, said Paul-Emmanuel Goethals, Co-Founder at MEDraysintell.
“A few years ago, when I was an executive working in radiopharmaceutical business development, I would have loved to have access to such a directory. Now it is available and we are very proud that the majority of the companies and product owners accepted, just prior to publication, to review, amend and complete individually the information we had collected about their activities” said Richard Zimmermann, Co-Founder at MEDraysintell.
More information and table of contents is available at: http://www.medraysintell.com/Nuclear_Medicine.html
Medical Radiation Strategic Intelligence Experts
Bringing value to Businesses and Investors
MEDraysintell was created in 2013 by Paul-Emmanuel Goethals (CSIntell) and Richard Zimmermann (Chrysalium Consulting). It combines over 40 years of experience in radiotherapy, particle therapy and nuclear medicine. We aim to form an international team of experts in the field of Medical Radiation to provide Strategic Intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy to help our clients better understand the markets and the competitive environment, as well as the potential of mergers and acquisitions (M&A) and technology development. MEDraysintell wants to support in their decisional process manufacturers of radiopharmaceuticals or therapeutic radioisotopes, suppliers of equipment and software, as well as investors interested in this industry.